Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IN8bio Inc. Common Stock
INAB | US
1.39
USD-0.04
-2.80%
INAB | US
About IN8bio Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
1.39
Open
1.44
High
1.46
Low
1.38
IN8bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200 a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100 an allogeneic product candidate which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400 which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300 INB-410 and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics Inc. and changed its name to IN8bio Inc. in August 2020. IN8bio Inc. was incorporated in 2016 and is headquartered in New York New York.
View LessINAB | US
Risk
115.9
Sharpe
-0.83
Luna's Score
40/100
Recommendation
Sell
Luna says (INAB | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
63.1%1 month
115.9%3 months
87.3%6 months
99.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.23
Debt to equity
0.43
Debt to assets
0.26
Ent. to EBITDA
-1.15
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-30.63M
MarketCap
100.84M
MarketCap(USD)
100.84M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-180.45
Short ratio
0.44
Short perc.
0.61
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.19
Range1M
0.76
Range3M
1.38
Volumes: Market Activity
Rel. volume
0.42
Price X volume
47.43K
